Evaluate the Performance of the PicoWayTM Picosecond Fractional Laser for Wrinkles Reduction

NCT02600104 | Unknown

• 1 other identifier: DHF17271
• Study Type: interventional
• Target: 74
• Locations: 1 country
• Sites: 4

Brief Summary

Prospective clinical study, Up to 100 healthy adult volunteers seeking Treatment of Wrinkles Reduction in the facial area, males or females of 18 to 75 years of age, from up to 5 investigational sites.

Conditions

Unwanted Wrinkles

Outcome Measures

Primary Outcomes (1)

• Efficacy of PicoWay for facial wrinkles reduction treatment assessed by blinded evaluators based on Fitzpatrick Classification and Degree of Elastosis.

  assessed by blinded evaluators.

  day 0 up to 9 months

Secondary Outcomes (4)

• Improvement in Fitzpatrick Classification and Degree of Elastosis, as assessed by study investigator

  from 3 weeks up to 9 months

• Safety of PicoWay treatment by Adverse events record during all study

  day 0 up to 9 months

• Evaluate investigator satisfaction assessed by questionnaire

  from 24 weeks up to 36 weeks

• Evaluate subject satisfaction assessed by questionnaire

  from 24 weeks up to 36 weeks

Study Arms (1)

all subjects

EXPERIMENTAL

will receive up to four (4) facial treatments in 3-8 weeks interval, with the PicoWayTM device-fractional hand piece 1064nm and/or 532nm according to the study protocol. Subjects will be followed by phone 7 days post first treatment by study staff, and will return for follow-up (FU) visits at the clinic at: 6 weeks and 12 weeks following the last treatment.

Device: PicoWayTM

Interventions

PicoWayTM DEVICE

The PicoWayTM base unit using a single, free-running, flashlamp-pumped alexandrite laser as a pump source for both the oscillator and the amplifier

all subjects

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Healthy female and male subjects between 18 to 75 years of age
• Has Fitzpatrick skin type I-VI
• Subjects seeking treatment for wrinkles reduction and willing to undergo laser treatments for improvement
• Have mild to moderate bilateral perioral and/or periorbital wrinkles
• Willing to receive the proposed PicoWayTM fractional treatments and comply with all study (protocol) requirements
• Willing to have photographs and images taken of the treated areas to be used in evaluations, publications and presentations (subject identity will be masked)
• For female subjects: not pregnant or lactating and is either post-menopausal, surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment (i.e., oral contraceptives, contraceptive implant, barrier methods with spermicide or abstinence)
• Informed consent process is completed and subject consent is signed

You may not qualify if:

• Pregnant or planning to become pregnant, having given birth less than 3 months ago, and/or breast feeding
• Hypersensitivity to light exposure
• Active sun tan in facial area
• Suffering from significant skin conditions in the treated areas or inflammatory skin conditions, including, but not limited to, open lacerations or abrasions, hidradenitis, or dermatitis of the treatment area prior to treatment (duration of resolution as per the Investigator's discretion) or during the treatment course
• Is taking medication(s) for which sunlight is a contraindication
• Has a history of squamous cell carcinoma or melanoma
• History of keloid scarring, abnormal wound healing and / or prone to bruising
• History of epidermal or dermal disorders (particularly if involving collagen or microvascularity), including collagen vascular disease or vasculitic disorders
• Has used oral isotretinoin (Accutane®) within 12 months of initial treatment or plans on using during the course of the study. Note: Skin must regain its normal degree of moisture prior to treatment, e.g., lack of noticeable skin flaking, skin peeling and skin surface roughness.
• A laser procedure, a peel or has used lightening creams that was performed in the area to be treated with the past six months
• History of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or currently using immunosuppressive medications
• Known allergy to lidocaine, tetracaine, Xylocaine or epinephrine
• Subjects with pigmented lesions that are considered not acceptable by the study investigator or any condition that, in the investigator's opinion, would make it unsafe to treat.
• As per the investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study

Sponsors & Collaborators

• Syneron Medical: lead

Study Sites (4)

Jerome M. Garden

Chicago, Illinois, 60611, United States

Location

Arielle N. Kauvar

New York, New York, 10028, United States

Location

Eric F. Bernstein

Ardmore, Pennsylvania, 19003, United States

Location

Tennessee Clinical Research Center

Nashville, Tennessee, 37215, United States

Location

Related Publications (1)

• Bloom BS, Emer J, Goldberg DJ. Assessment of safety and efficacy of a bipolar fractionated radiofrequency device in the treatment of photodamaged skin. J Cosmet Laser Ther. 2012 Oct;14(5):208-11. doi: 10.3109/14764172.2012.724534.

  PMID: 23016529 BACKGROUND

Study Officials

• Eric F Bernstein, M.D.

  Main Line Center for Laser Surgery

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 28, 2015
• First Posted: November 9, 2015
• Study Start: June 10, 2015
• Primary Completion: December 1, 2017
• Study Completion: December 1, 2018
• Last Updated: April 4, 2017

Record last verified: 2017-04

Locations

US (4)